ArticleImmunity & ageing : I & A2026
Immune risk phenotype and long-term mortality after community-acquired pneumonia in older adults: clinical and immune determinants.
Article in Immunity & ageing : I & A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCommunity-acquired pneumonia (CAP) has been associated with poor long-term outcomes in older adults. In most pre-pandemic studies, long-term mortality was assessed with a focus on comorbidity burden. Although immunosenescence is a key determinant of CAP, post-acute immune patterns have been little explored.
objectiveTo assess 18-month mortality after CAP hospitalisation and the prognostic value of the Immune Risk Phenotype (IRP).
methodsProspective, observational study of adults ≥ age 65 years discharged after CAP (2019-21). We performed comprehensive geriatric and nutritional assessments, including laboratory tests at 30-60 days post diagnosis. IRP was defined as cytomegalovirus seropositivity with inverted CD4:CD8 ratio, elevated CD8 + T cell count, or expansion of CD8CD28-T cells. The main outcome measure was 18-month mortality. Multivariate logistic with ROC curves and Cox regression analyses were performed. (ClinicalTrials.gov, NCT0462799).
resultsThe sample included 143 patients (55.2% males), with a mean age of 77.6 ± 7.9 years. IRP was found in 46.8% of patients. Elevated lymphocyte count and female sex were predictors of IRP. At 18 months post-CAP, 27 patients (18%) had died, mainly due to infections (n = 13, 48%) and fractures (n = 2, 7.4%). Predictors of 18-month mortality included IRP (HR 2.58 [95% CI 1.11-5.99]; p = 0.027), severe chronic kidney disease (6.16 [2.53-14.99]; p<0.001), poor functional status (3.69 [1.53-8.90] p = 0.004), and hypoalbuminemia (3.35; [1.34-8.41]; p = 0.010).
conclusionsThis study underscores the role of infectious complications in long-term outcomes after CAP. These findings highlight the need for comprehensive geriatric assessment to identify multidimensional risk factors, including immunosenescence as a potentially modifiable domain warranting further investigation and integration into care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.